Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid

Summary A competitive enzyme-linked immunosorbent assay with high sensitivity has been developed for measuring ubiquitin reactivity of paired helical filaments (PHF). Using the assay, ubiquitin immunoreactivity was estimated in the cerebrospinal fluid (CSF) of 44 patients who had been clinically diagnosed as having Alzheimer's disease (AD) and of 38 control patients, including 20 neurological cases. Monoclonal antibody (mAb) 5–25 to isolated paired helical filaments was used. This mAb recognizes amino acids 64–76 of ubiquitin. The levels of ubiquitin immunoreactivity measured in CSF (twice diluted) were significantly higher in the AD (p<0.001) than in the control group. In only a minority of instances were values for ubiquitin levels the same in AD and control groups: on PHF-coated plates, immunoreactivity values for 77% of the AD CSF specimens were higher than those for 92% of the controls, and on ubiquitin-coated plates, values for 85% of the AD CSF specimens were higher than those for 88% of the controls. On immunoblots of both AD and control CSF, mAb 5-25 stained a series of protein bands. The free ubiquitin that is also present in the CSF was not labeled. No striking differences were detected in the immunoblot pattern of AD and control CSF. This study demonstrastes the presence of quantitative differences in the conjugated ubiquitin in AD and control CSF.Supported in part by the NYS Office of Mental Retardation and Developmental Disabilities; NIH grants NS18105, AG05892, and AG04220; and a grant from Senetek PLCA preliminary report on part of these findings was presented at The First International Conference on Alzheimer Disease & Related Disorders (Alzheimer Disease Assoc. Disord. 2:175, 1988)